A detailed history of Globeflex Capital L P transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Globeflex Capital L P holds 22,202 shares of NBIX stock, worth $3.01 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares
22,202
Previous 21,499 3.27%
Holding current value
$3.01 Million
Previous $2.96 Million 13.62%
% of portfolio
0.25%
Previous 0.31%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$114.58 - $153.15 $80,549 - $107,664
703 Added 3.27%
22,202 $2.56 Million
Q2 2024

Aug 13, 2024

SELL
$130.86 - $143.19 $188,045 - $205,764
-1,437 Reduced 6.27%
21,499 $2.96 Million
Q4 2023

Feb 13, 2024

BUY
$106.07 - $132.76 $188,910 - $236,445
1,781 Added 8.42%
22,936 $3.02 Million
Q2 2023

Aug 14, 2023

SELL
$89.53 - $104.87 $350,151 - $410,146
-3,911 Reduced 15.6%
21,155 $1.99 Million
Q1 2023

May 12, 2023

BUY
$94.11 - $123.02 $736,693 - $963,000
7,828 Added 45.41%
25,066 $2.54 Million
Q4 2022

Feb 10, 2023

BUY
$106.72 - $127.06 $609,157 - $725,258
5,708 Added 49.51%
17,238 $2.06 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $1.06 Million - $1.24 Million
11,530 New
11,530 $1.23 Million
Q4 2020

Feb 11, 2021

SELL
$86.91 - $108.33 $489,477 - $610,114
-5,632 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$96.16 - $135.15 $96,063 - $135,014
-999 Reduced 15.07%
5,632 $542,000
Q2 2020

Aug 12, 2020

SELL
$85.09 - $130.36 $224,382 - $343,759
-2,637 Reduced 28.45%
6,631 $809,000
Q4 2019

Feb 07, 2020

BUY
$86.8 - $118.57 $804,462 - $1.1 Million
9,268 New
9,268 $996,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Globeflex Capital L P Portfolio

Follow Globeflex Capital L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Globeflex Capital L P, based on Form 13F filings with the SEC.

News

Stay updated on Globeflex Capital L P with notifications on news.